Skip to content

Effects of Intermittent Caloric Restriction in Youth With Cardiometabolic Risk

Effects of Intermittent Caloric Restriction in Youth With Cardiometabolic Risk: a Randomized Controlled Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04011995
Enrollment
34
Registered
2019-07-09
Start date
2018-07-12
Completion date
2021-12-01
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Risk, Obesity, Overweight

Keywords

Intermittent caloric restriction, Children, Youth

Brief summary

This is a randomized controlled pilot study to evaluate the effects of intermittent caloric restriction compared with low carbohydrate diet in youth with cardiometabolic risk.

Detailed description

The National China Health and Nutrition Survey revealed that 42% of overweight children had at least one cardiovascular metabolic risk, such as hyperglycaemia, dyslipidemia or hypertension. Non-pharmaceutical life style modifications are the recommended intervention to these subjects, including caloric restriction and increased physical activity. However, the problems of poor compliance and metabolic adaptation are well known. Evidences from a number studies in rodent models and human indicated that intermittent caloric restriction (ICR) may stimulate series reactions in human body, including improvement of insulin sensitivity, blood pressure, oxidative stress and inflammation, and may be easier to follow. Evidence from larger human studies is strongly encouraged, while the effects, safety and adherence in chidren and youth need to be studied. This study is a randomized controlled trial of intermittent caloric restriction versus low carbohydrate diet in youth with cardiometabolic risk over one month period. The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. For control group, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention during the 14-day intervention period,. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted. The study aim to explore effects of the dietary interventions on cardiometabolic markers, inflammatory reaction, oxidative stress and gut microbiome in youth with cardiometabolic risk.

Interventions

The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.

BEHAVIORALLow carbohydrate diet

During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.

BEHAVIORALHealth education on reducing the cardiometabolic risk

Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.

Sponsors

Children's Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

Have at least one of the following cardiometabolic abnormalities: 1. Overweight or obesity (central obesity or general obesity) 2. Prediabetes: impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) 3. Dyslipidemia 4. Elevated blood pressure Criteria for cardiometabolic abnormalities: 1. Overweight or obesity For subjects (9 ≤ age ≤ 18 years) : • General obesity: Body mass index higher than the 85th percentile for overweight and the 90th percentile for obesity, based on the references for screening overweight and obesity in Chinese children and adolescents. • Central obesity: Waist circumference higher than the 90th percentile of the age and gender-specific reference for screening cardiovascular risk factors in Chinese children and adolescents. For subjects ( 19 ≤ age ≤ 30 years) : • General obesity: Body mass index between 24.0 and 27.9 kg/m2 for overweight and ≥28 kg/m2 for obesity. • Central obesity: Waist circumference ≥85cm for men and ≥80cm for female. Based on recommendation of overweight and obesity in Chinese adults. 2. Prediabetes: With IFG and/or IGT. IFG: fasting glucose from 5.6 to 6.9 mmol/L; IGT: 2-h glucose in the 75g oral glucose tolerance test from 7.8 to 11.0 mmol/L. Based on recommendation of American Diabetes Association. 3. Dyslipidemia: For subjects (9 ≤ age ≤ 18 years) : Triglycerides of ≥1.70 mmol/L or total cholesterol of ≥5.18 mmol/L or lowdensity lipoprotein cholesterol ≥3.37 mmol/L or highdensity lipoprotein cholesterol of ≤1.04 mmol/L. Based on recommendation in Chinese children and adolescents. For subjects ( 19 ≤ age ≤ 30 years) : Triglycerides of ≥1.7 mmol/L or total cholesterol of ≥5.2 mmol/L or lowdensity lipoprotein cholesterol ≥3.4 mmol/L or highdensity lipoprotein cholesterol of ≤1.0 mmol/L. Based on guideline for the management of dyslipidemia in Chinese adults. 4. Elevated blood pressure: For subjects (9 ≤ age ≤ 18 years) : Blood pressure higher than the 90th percentile of blood pressure age and gender-specific reference standards for Chinese children and adolescents, or blood pressure \>120/80 mmHg. For subjects ( 19 ≤ age ≤ 30 years) : Systolic blood pressure≥120 mmHg and/or diastolic blood pressure ≥80 mmHg. Based on Chinese guidelines for the management of hypertension.

Exclusion criteria

1. Diagnosis of severe diseases such as cardiac insufficiency, severe malnutrition or immunodeficiency. 2. History of bariatric surgery. 3. Use of antiobesity drugs or supplements.

Design outcomes

Primary

MeasureTime frameDescription
Reversal of cardiometabolic abnormalitiesFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.The primary outcome is a composite outcome that will be measured by combining multiple reverse outcomes of the following cardiometabolic abnormalities: (1) overweight or obesity, (2) prediabetes, (3) hyperlipidemia and (4) elevated blood pressure. It is defined as occurring if any cardiometabolic abnormality has a reversal outcome at the 14th day of dietary intervention phase. Reversal of cardiometabolic abnormalities is defined as: At the 14th day of dietary intervention phase, at least one of the following indicators changed from abnormal at baseline to normal: overweight, obesity, prediabetes, hyperlipidemia and elevated blood pressure. (The reversal of overweight or obesity is defined according to reference\[1, 2\]: For subject with general obesity at baseline: weight loss of 1.5 kg after intervention; For subject with central obesity at baseline: waist circumference reduction of 1.5 cm after intervention.)

Secondary

MeasureTime frameDescription
Change in gut microbial compositionsFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Stool sample of subject is used for measurement of gut microbial compositions.
Change in insulinFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Serum from fasting blood sample is used for measurement of insulin.
Change in insulin-like growth factor-1From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Fasting blood sample for measurement of insulin-like growth factor-1.
Change in body weightFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Body weight is measured according to the Physical Fitness and Health Surveillance of Chinese School Students by trained, certified study staff. It is measured to the nearest 0.1 kg.
Change in waist circumferenceFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Waist circumference is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled. It is calculated as the average value of two measurements.
Change in mean blood glucoseFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Measured by a blood glucose monitor for 24-hour glucose monitoring during the 14-day intervention phase.
Self-reported dietary adherenceAt the 14th day of the self-maintenance phase.Adherence to diet will be assessed with a electronic questionnaire in the self-maintenance phase.
Change in monocyte chemoattractant protein-1 (MCP-1)From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.MCP-1 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Change in free fatty acid (FFA)From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.FFA will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Change in fibroblast growth factor 21 (FGF-21)From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.FGF-21 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Dietary energy intakeFrom the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.Daily dietary energy intake (kcals/day) is calculated by researchers using food weighing photos of the subject.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026